Tempus AI Surges: ADLT Pricing Rewrites the Earnings Outlook
2026/09/18 07:15By:
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Tempus AI (NASDAQ: TEM) has once again become one of the most closely watched names in the AI healthcare sector. From September 14 to September 17, the stock surged from around $59 to $80.36. It gained 10.7% on September 15 and another 14.85% on September 17, bringing its four-day advance to more than 36%.
The key catalyst came from the Morgan Stanley Healthcare Conference, where management provided a much clearer quantification of how ADLT pricing could affect the company’s diagnostics revenue and profitability. The market is now reassessing Tempus’ growth trajectory over the next two years.
ADLT Pricing Becomes a New Growth Lever
Tempus received FDA approval for xT Tumor Only earlier this year, allowing the company to gradually migrate the core solid-tumor test toward the ADLT pricing framework. At the Morgan Stanley conference, CEO Eric Lefkofsky said the pricing transition alone could generate roughly $80 million to $100 million in additional revenue next year, while also contributing to improved profitability and free cash flow.
An even larger potential catalyst comes from liquid biopsy.
Tempus is currently advancing its liquid biopsy product through the FDA approval process. Management had previously expected reimbursement of roughly $5,000 to $6,000 per test. Based on recent ADLT pricing granted to competing products, however, the company now believes eventual pricing could reach around $7,000 to $8,000.
At current testing volumes, management estimates that this change could eventually generate approximately $250 million to $300 million in annualized incremental revenue.
This means Tempus’ diagnostics business could increasingly benefit from two growth drivers at the same time: higher testing volumes and higher revenue per test. Because much of the laboratory, sales, and data infrastructure is already in place, higher reimbursement pricing could also produce greater profit leverage than volume growth alone.
Fundamentals Are Starting to Support the AI Healthcare Story
One of Tempus’ main advantages is that its AI narrative is already built on top of a scaled healthcare business.
Second-quarter revenue reached $382.5 million, up 22% year over year. Oncology testing volumes increased 31%, while Data Licensing & Modeling revenue grew 36%. The company also signed approximately $200 million of new data and application licensing agreements during the quarter.
Adjusted EBITDA reached $8 million, while Tempus raised its 2026 revenue guidance to between $1.595 billion and $1.605 billion and maintained its full-year Adjusted EBITDA target of approximately $65 million.
The data business is particularly important. Tempus continuously generates structured clinical and molecular data through its diagnostics operations, then uses those datasets for drug development, patient selection, and AI model training.
This year, the company delivered its first oncology foundation model to AstraZeneca, indicating that its data assets are beginning to move beyond traditional licensing and toward higher-value AI applications.
Personalis Pushes MRD Toward the Next Growth Curve
In July, Tempus announced the acquisition of Personalis at an enterprise value of approximately $1.5 billion, significantly strengthening its position in minimal residual disease, or MRD, testing.
Tempus reported roughly 9,000 MRD tests in the second quarter, up from around 6,500 in the previous quarter, suggesting that demand in this market is already expanding rapidly.
Personalis’ NeXT Personal technology allows Tempus to deepen its exposure to post-treatment recurrence monitoring. This expands the company’s presence beyond cancer diagnosis and treatment selection into longer-term disease monitoring.
If Tempus can integrate Personalis’ testing capabilities with its existing hospital, physician, and data networks, MRD could become another major revenue driver over the next several years.
The acquisition also creates execution risk. A $1.5 billion transaction is substantial, and Tempus will need to demonstrate that revenue synergies, reimbursement progress, and testing-volume growth can justify the integration costs while limiting financing and potential dilution pressure.
A $14.5 Billion Valuation Now Demands Faster Execution
TEM currently carries a market capitalization of roughly $14.5 billion. Based on the midpoint of the company’s 2026 revenue guidance of approximately $1.6 billion, the stock trades at around 9x forward sales. Using trailing twelve-month revenue of roughly $1.43 billion, its trailing price-to-sales multiple is already above 10x.
That valuation reflects substantial expectations for future growth, including higher ADLT reimbursement, liquid biopsy approval, MRD expansion, Personalis synergies, and continued growth across the company’s data and AI businesses.
Tempus’ fundamentals are clearly improving, but the margin for execution error has narrowed significantly. Any disappointment in FDA approvals, reimbursement pricing, or testing-volume growth could therefore trigger a meaningful valuation reset.
After Breaking $80, Historical Highs Come Back Into Focus
From a technical perspective, TEM reached an intraday high of $81.26 on September 17 and closed near the session high on significantly stronger volume, making the $80 area an important short-term breakout zone.
The first support area sits around $69 to $72, which acted as a trading cluster in late August and again during the latest rally. A deeper support zone lies around $61 to $63.
On the upside, the more important resistance comes from previous historical highs. TEM’s record closing high stands at $103.25, meaning that after the breakout above $80, the $90 level and the $100–103 region are likely to attract increasing market attention.
If the stock can consolidate above $80, the bullish structure could remain intact. A rapid move back below $70, however, would suggest that the valuation re-rating driven by ADLT expectations is entering a longer digestion phase.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US space stocks rally this week: SpaceX(SPCX.US) Starship's first revenue-generating flight is imminent, Voyager(VOYG.US) and Rocket Lab(RKLB.US) surge
U.S. space stocks will encounter multiple catalysts this week.
智通财经•2026/09/18 08:56
AI Demand Ignites the Green Energy Sector! These 5 Stocks Have Quietly Soared This Year, With the Highest Up Over 223%
Some green energy companies in the sustainable development sector have quietly outperformed many popular peers.
智通财经•2026/09/18 08:41
Tech stocks rebound strongly, Nasdaq futures up 0.7%, yen under pressure, Brent oil down 2% intraday.
Nvidia's optimistic earnings outlook has driven further rebounds in chip stocks. Nasdaq 100 index futures are up 0.7%, and S&P 500 index futures are up 0.4%. The US dollar has risen 1% against the yen, trading at 157.53. Bank of Japan Governor Kazuo Ueda says it is difficult to judge whether the financial environment is excessively loose. Brent crude has fallen 2.0% intraday, trading at $97.92 per barrel. On Friday, the market also faces additional disruptions brought by "triple witching day."
华尔街见闻•2026/09/18 08:26
